Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jan 24;2007(1):CD004761.
doi: 10.1002/14651858.CD004761.pub2.

Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders

J R Overell  1 , S T Hsieh, M Odaka, N Yuki, H J Willison
Affiliations

Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders

J R Overell et al. Cochrane Database Syst Rev. .

Abstract

Background: Fisher syndrome is one of the regional variants of Guillain-Barré syndrome, characterised by impairment of eye movements (ophthalmoplegia), incoordination (ataxia) and loss of tendon reflexes (areflexia). It can occur in more limited forms, and may overlap with Guillain-Barré syndrome. A further variant is associated with upper motor neuron signs and disturbance of consciousness (Bickerstaff's brainstem encephalitis). All of these variants are associated with anti-GQ1b IgG antibodies. Intravenous immunoglobulin (IVIg) and plasma exchange are often used as treatments in this patient group. This review was undertaken to systematically assess any available randomised controlled data on acute immunomodulatory therapies in Fisher Syndrome or its variants.

Objectives: To provide the best available evidence from randomised controlled trials on the role of acute immunomodulatory therapy in the treatment of Fisher Syndrome and related disorders.

Search strategy: We searched the Cochrane Neuromuscular Disease Trials register (March 2004), MEDLINE (from January 1966 to November 2004), EMBASE (from January 1980 to November 2004), CINAHL (from January 1982 to November 2004) and LILACS (from January 1982 to November 2004) for randomised controlled trials, quasi-randomised trials, historically controlled studies and trials with concurrent controls. We adapted this strategy to search MEDLINE from 1966 and EMBASE from 1980 for comparative cohort studies, case-control studies and case series.

Selection criteria: All randomised and quasi-randomised controlled clinical trials (in which allocation was not random but was intended to be unbiased, e.g. alternate allocation, and non-randomised controlled studies were to have been selected. Since no such clinical trials were discovered, all retrospective case series containing five or more patients were assessed and summarised in the discussion section.

Data collection and analysis: All studies of Fisher Syndrome and its clinical variants were scrutinised for data on patients treated with any form of acute immunotherapy. Information on the outcome was then collated and summarised.

Main results: We found no randomised or non-randomised prospective controlled trials of immunotherapy in Fisher Syndrome or related disorders. We summarised the results of retrospective series containing five or more patients in the discussion section.

Authors' conclusions: There are no randomised controlled trials of immunomodulatory therapy in Fisher Syndrome or related disorders on which to base practice.

PubMed Disclaimer

Conflict of interest statement

None

Update of

References

Additional references

Al Din 1982
    1. Al‐Din AN, Anderson M, Bickerstaff ER, Harvey I. Brainstem encephalitis and the syndrome of Miller Fisher: a clinical study. Brain 1982;105(Pt 3):481‐95. - PubMed
Asbury 1990
    1. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain‐Barré syndrome. Annals of Neurology 1990;27 Suppl:S21‐4. - PubMed
Barontini 1983
    1. Barontini F, Sita D. The nosological position of Fisher's syndrome (ophthalmoplegia, ataxia and areflexia). Journal of Neurology 1983;229(1):33‐44. - PubMed
Bickerstaff 1957
    1. Bickerstaff ER. Brainstem encephalitis: further observations on a grave syndrome with benign prognosis. British Medical Journal. 1 1957; Vol. 15 (5032):1384‐7. - PMC - PubMed
Cheng 2003
    1. Cheng BC, Chang WN, Chang CS, Chee CY, Huang CR, Chen JB, et al. Guillain‐Barré syndrome in southern Taiwan: clinical features, prognostic factors and therapeutic outcomes. European Journal of Neurology 2003;10(6):655‐62. - PubMed
Chiba 1992
    1. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Annals of Neurology 1992;31(6):677‐9. - PubMed
Chiba 1993
    1. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti‐GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain‐Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43(10):1911‐7. - PubMed
Fisher 1956
    1. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). New England Journal of Medicine. 255 1956; Vol. 255, issue 2:57‐65. - PubMed
Halstead 2008
    1. Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, et al. Eculizumab prevents anti‐ganglioside antibody‐mediated neuropathy in a murine model. Brain 2008;131 (Pt 5):1197‐208. - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration 2009. Available from www.cochrane‐handbook.org.
Hughes 1997
    1. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain‐Barré syndrome. Journal of Infectious Diseases 1997;176(Suppl 2):S92‐8. - PubMed
Hughes 2006a
    1. Hughes RAC, Swan AV, Koningsveld R, Doorn P. Corticosteroids for treating Guillain‐Barré syndrome. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD001446.pub2] - DOI - PubMed
Hughes 2006b
    1. Hughes RAC, Raphael JC, Swan AV, Doorn PA. Intravenous immunoglobulin for Guillain‐Barré syndrome. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD002063.pub3] - DOI - PubMed
Italian Guillain‐Barré Study Group 1996
    1. The Italian Guillain‐Barré Study Group. The prognosis and main prognostic indicators of Guillain‐Barré syndrome: a multicentre prospective study of 297 patients. Brain 1996;119(Pt 6):2053‐61. - PubMed
Ito 2008
    1. Ito M, Kuwabara S, Odaka M, Misawa S, Koga M, Hirata K, Yuki N. Bickerstaff's brainstem encephalitis and Fisher Syndrome form a continuous spectrum. Journal of Neurology 2008;255(5):674‐82. - PubMed
Jacobs 2003
    1. Jacobs BC, O'Hanlon GM, Bullens RW, Veitch J, Plomp JJ, Willison HJ. Immunoglobulins inhibit pathophysiological effects of anti‐GQ1b‐positive sera at motor nerve terminals through inhibition of antibody binding. Brain 2003;126(Pt 10):2220‐34. - PubMed
Kobayashi 1983
    1. Kobayashi I, Takemiya T, Maruyama S. Physiological analysis of Fisher's syndrome. No to Shinkei 1983;35(4):385‐94. - PubMed
Koga 1998
    1. Koga M, Yuki N, Takahashi M, Saito K, Hirata K. Close association of IgA anti‐ganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain‐Barré and Fisher's syndromes. Journal of Neuroimmunology 1998;81(1‐2):138‐43. - PubMed
Koga 2005
    1. Koga M, Gilbert M, Li J, Koike S, Takahashi M, Furukawa K, et al. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology 2005;64(9):1605‐11. - PubMed
Kuntzer 1987
    1. Kuntzer T, Bogousslavsky J, Regli F. Benign encephalitis of the brain stem. Revue Neurologique 1987;143(11):737‐45. - PubMed
Lee 2008
    1. Lee S‐H, Lim G‐H, Kim JS, Oh S‐Y, Kim JK, Cha J‐K, et al. Acute Ophthalmoplegia (without ataxia) associated with anti‐GQ1b antibody. Neurology 2008;71(6):426‐9. - PubMed
Lyu 1997
    1. Lyu RK, Tang LM, Cheng SY, Hsu WC, Chen ST. Guillain‐Barré syndrome in Taiwan: a clinical study of 167 patients. Journal of Neurology, Neurosurgery and Psychiatry 1997;63(4):494‐500. - PMC - PubMed
Mizoguchi 1998
    1. Mizoguchi K. Anti‐GQ1b IgG antibody activities related to the severity of Miller Fisher syndrome. Neurological Research 1998;20(7):617‐24. - PubMed
Mori 2001
    1. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001;56(8):1104‐6. - PubMed
Mori 2002
    1. Mori M, Kuwabara S, Fukutake T, Hattori T. Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases. Journal of Neurology Neurosurgery and Psychiatry 2002;72(5):680. - PMC - PubMed
Mori 2007
    1. Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller Fisher Syndrome. Neurology 2007;68(14):1144‐6. - PubMed
Mukai 1978
    1. Mukai E, Takahashi A, Koike Y, Sobue I, Koto Y. Clinical analysis of seven cases of Fisher's syndrome (author's transl)]. Rinsho Shinkeigaku 1978;18(4):213‐9. - PubMed
Nishimoto 2004
    1. Nishimoto Y, Odaka M, Hirata K, Yuki N. Usefulness of anti‐GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. Journal of Neuroimmunology 2004; Vol. 148, issue 1‐2:200‐5. - PubMed
O'Hanlon 2003
    1. O'Hanlon GM, Humphreys PD, Goldman RS, Halstead SK, Bullens RW, Plomp JJ, et al. Calpain inhibitors protect against axonal degeneration in a model of anti‐ganglioside antibody‐mediated motor nerve terminal injury. Brain 2003;126(Pt 11):2497‐509. - PubMed
Odaka 2003
    1. Odaka M, Yuki N, Yamada M, Koga M, Takemi T, Hirata K, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain‐Barré syndrome. Brain 2003;126(Pt 10):2279‐90. - PubMed
Odaka 2003a
    1. Odaka M, Koga M, Yuki N, Susuki K, Hirata K. Longitudinal changes of anti‐ganglioside antibodies before and after Guillain‐Barré syndrome onset subsequent to Campylobacter jejuni enteritis. Journal of the Neurological Sciences 2003;210(1‐2):99‐103. - PubMed
Raphaël 2002
    1. Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain‐Barré syndrome. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD001798] - DOI - PubMed
Rees 1998
    1. Rees JH, Thompson RD, Smeeton NC, Hughes RAC. Epidemiological study of Guillain‐Barré syndrome in south east England. Journal of Neurology Neurosurgery and Psychiatry 1998;64(1):74‐7. - PMC - PubMed
Shuaib 1987
    1. Shuaib A, Becker WJ. Variants of Guillain‐Barré syndrome: Miller Fisher syndrome, facial diplegia and multiple cranial nerve palsies. Canadian Journal of Neurological Sciences 1987;14(4):611‐6. - PubMed
Susuki 2001
    1. Susuki K, Yuki N, Hirata K. Fine specificity of anti‐GQ1b IgG and clinical features. Journal of the Neurological Sciences 2001;185(1):5‐9. - PubMed
van Koningsveld 2004
    1. Koningsveld R, Schmitz PIM, Meché FGA, Visser LH, Meulstee J, Doorn PA, for the Dutch GBS study group. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain‐Barré syndrome: randomised trial. Lancet 2004;363(9404):192‐6. - PubMed
Willison 1993
    1. Willison HJ, Veitch J, Paterson G, Kennedy PGE. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. Journal of Neurology Neurosurgery and Psychiatry 1993;56(2):204‐6. - PMC - PubMed
Willison 2004
    1. Willison HJ, Townson K, Veitch J, Boffey J, Isaacs N, Andersen SM, et al. Synthetic disialylgalactose immunoadsorbents deplete anti‐GQ1b antibodies from autoimmune neuropathy sera. Brain 2004;127(Pt 3):680‐91. - PubMed
Yaqub 1990
    1. Yaqub BA, Al‐Deeb SM, Daif AK, Sharif HS, Shamena AR, Al‐Jaberi M, et al. Bickerstaff brainstem encephalitis: a grave non‐demyelinating disease with benign prognosis. Journal of the Neurological Sciences 1990;96(1):29‐40. - PubMed
Yeh 1999
    1. Yeh JH, Chen WH, Chen JR, Chiu HC. Miller Fisher syndrome with central involvement: successful treatment with plasmapheresis. Therapeutic Apheresis 1999;3(1):69‐71. - PubMed
Yin 1985
    1. Yin PA. Fisher's syndrome‐‐report of 7 cases. Zhonghua Shen Jing Jing Shen Ke Ka Zhi 1985;18(1):27‐9. - PubMed
Yip 1991
    1. Yip PK, Tsai SY, Chen RC. The syndrome of ophthalmoplegia, ataxia and areflexia (Fisher's syndrome): clinical analysis of 9 cases. Zhonghua Yi Xue Za Zhi (Taipei) 1991;47(2):126‐32. - PubMed
Yuki 1993
    1. Yuki N, Sato S, Tsuji S, Hozumi I, Miyatake T. An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. Journal of the Neurological Sciences 1993;118(1):83‐7. - PubMed
Yuki 1993a
    1. Yuki N, Sato S, Tsuji S, Ohsawa T, Miyatake T. Frequent presence of anti‐GQ1b antibody in Fisher's syndrome. Neurology 1993;43(2):414‐7. - PubMed
Yuki 1996
    1. Yuki N. Tryptophan‐immobilized column adsorbs immunoglobulin G anti‐GQ1b antibody from Fisher's syndrome: a new approach to treatment. Neurology 1996;46(6):1644‐51. - PubMed
Yuki 2000
    1. Yuki N, Susuki K, Hirata K. Ataxic Guillan‐Barre syndrome with anti‐GQ1b antibody: relation to Miller Fisher syndrome. Neurology 2000;54(9):1851‐3. - PubMed
Yuki 2001
    1. Yuki N. Infectious origins of, and molecular mimicry in, Guillain‐Barré and Fisher syndromes. Lancet Infectious Diseases 2001;1(1):29‐37. - PubMed
Yuki 2001a
    1. Yuki N, Odaka M, Hirata K. Acute ophthalmoparesis (without ataxia) associated with anti‐GQ1b IgG antibody. Ophthalmology 2001;108(1):196‐200. - PubMed
Yuki 2005
    1. Yuki N. Carbohydrate mimicry: a new paradigm of autoimmune diseases. Current Opinion in Immunology 2005;17(6):577‐82. - PubMed

Publication types